Assess the Effect of Daily Purgation therapy with small doses of medicine alongwith External panchakarma therapy in Diabetic peripheral neuropathy disease
Phase 3
Completed
- Conditions
- Health Condition 1: - Health Condition 2: - Health Condition 3: G64- Other disorders of peripheral nervous systemHealth Condition 4: G63- Polyneuropathy in diseases classified elsewhere
- Registration Number
- CTRI/2022/03/041400
- Lead Sponsor
- Institute of Teaching and Research in Ayurveda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
1)Known case of type2 diabetes mellitus.
2)Presence of any classical symptoms-
Burning sensation
Pain
Numbness
Tingling sensation
Insensitivity to hot or cold in feet.
3)Patients of both genders.
Exclusion Criteria
1)Patients having any other associated clinical complication like
cancer
T.B
Local skin infection
wound
Diabetic foot
2)Type1 diabetes.
3)Age below 30 years and age above 75years.
4)Pregnant and Lactating women.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1)Observing signs and symptoms of Patients in Diabetic peripheral neuropathy- Tingling sensation,Numbness,Burning sensation,Prickling sensation through symptoms grading score. <br/ ><br>2)Modified toronto clinical neuropathy score(mTCNs) <br/ ><br>3)Vibration and Thermal threshold test by Neuropathy analyser machine Biothesiometer. <br/ ><br>4)Monofilament test <br/ ><br>5)Laboratory invetigation- <br/ ><br>FBS,PP2BS <br/ ><br>LIPID PROFILE <br/ ><br>URINE INV. <br/ ><br>Haematological <br/ ><br>Vitamin B12(before treatment ) <br/ ><br>Timepoint: Before starting of Treatment and after 15 days of completion of treatment
- Secondary Outcome Measures
Name Time Method 1)Changes in signs and symptoms of Diabetic peripheral neuropathy <br/ ><br>2)changes in Modified toronto clinical neuropathy score <br/ ><br>3)changes in Biothesiometer reading <br/ ><br>4)changes in monofilament test <br/ ><br>5)changes in FBS and PP2BS <br/ ><br>Timepoint: Patients will be assessed before treatment and after 15days completion of treatment